Background: 68Gallium (68Ga) -ligand- (PSMA) is a new radiotracer with great diagnostic potential in prostate cancer patients. The imaging is usually performed using PET/CT system, and PET/MRI system when available.The results of PSMA PET/CT in identifying intra-prostatic disease are very impressive. The use of PSMA PET/CT has a higher detection rate of predicted local or distant metastasis compared to CT.
Aim of the Work: The aim of this study is to appraise the added value of 68Gallium PSMA PET/CT over the contrast enhanced CT in patients with prostatic cancer.
Patients and Methods: The study included 29 male patients in this comparative study (their aged ranged from 50 and 75 years, with mean age of 64.28 years), (the mean of PSA level was 16.86 with range from 0.02 to 150) were referred to the PET/CT unit with different scenarios related to prostate cancer (Biochemical recurrence, initial staging and follow up) at MISR Radiology Center “MRC" in Cairo, Egypt using hybrid PET/CT machine (PET/CT 128 slices machine). Comparative 68Ga-PSMA PET/CT and contrast enhanced CT scans were conducted for all patients. Each patient included in the study was subjected to full history taking and reviewing PSA and serum creatinine levels.
Results: 68Ga PSMA PET showed high accuracy in the detection of the prostate cancer, seminal vesicles invasion, local and distant lymph nodes metastasis, lung metastasis, liver metastasis and bone metastasis compared to CECT.